Garry A. Nicholson - 12 Sep 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Director
Signature
/s/ Charles N. York II, as Attorney-in-Fact for Reporting Person
Issuer symbol
DAWN
Transactions as of
12 Sep 2022
Net transactions value
$0
Form type
4
Filing time
14 Sep 2022, 19:34:00 UTC
Previous filing
17 Aug 2022
Next filing
16 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Stock Option (Right to buy Common Stock) Award $0 +33,900 $0.000000 33,900 12 Sep 2022 Common Stock 33,900 $25.84 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on October 12, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.